IN2012DN02861A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02861A
IN2012DN02861A IN2861DEN2012A IN2012DN02861A IN 2012DN02861 A IN2012DN02861 A IN 2012DN02861A IN 2861DEN2012 A IN2861DEN2012 A IN 2861DEN2012A IN 2012DN02861 A IN2012DN02861 A IN 2012DN02861A
Authority
IN
India
Prior art keywords
relates
pharmaceutical compositions
compositions
igf
insulin
Prior art date
Application number
Inventor
Enona Gopinath
Susan Park
Tsutomu Arakawa
Joel Richard
Fabio Fais
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of IN2012DN02861A publication Critical patent/IN2012DN02861A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to pharmaceutical compositions. More particularly, the invention relates to formulations of growth hormone (GH) and insulin-like growth factor (IGF-1) combination compositions which provide stable pharmaceutical compositions without aggregation formation at a desirable pH, and to processes of preparation thereof.
IN2861DEN2012 2009-11-17 2010-11-17 IN2012DN02861A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26185909P 2009-11-17 2009-11-17
PCT/EP2010/006996 WO2011060922A1 (en) 2009-11-17 2010-11-17 Formulation for hgh and rhigf-1 combination

Publications (1)

Publication Number Publication Date
IN2012DN02861A true IN2012DN02861A (en) 2015-07-24

Family

ID=43661042

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2861DEN2012 IN2012DN02861A (en) 2009-11-17 2010-11-17

Country Status (15)

Country Link
US (2) US20120270782A1 (en)
EP (1) EP2501367B1 (en)
JP (2) JP6084036B2 (en)
KR (1) KR101614983B1 (en)
CN (1) CN102665691B (en)
AU (1) AU2010321225B2 (en)
BR (1) BR112012011539A8 (en)
CA (1) CA2780554C (en)
ES (1) ES2532007T3 (en)
HK (1) HK1175711A1 (en)
IN (1) IN2012DN02861A (en)
MX (1) MX2012005195A (en)
RU (1) RU2558821C2 (en)
UA (1) UA108994C2 (en)
WO (1) WO2011060922A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158582B2 (en) 2005-06-02 2012-04-17 Tercica, Inc. Methods for treatment of insulin-like growth factor-1 deficiency
BR112014001921B1 (en) 2011-07-25 2022-05-10 Sandoz Ag Pharmaceutically acceptable aqueous formulation, method of increasing the stability of a pharmaceutically acceptable aqueous formulation and main packaging
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
CN104371019B (en) 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 It is a kind of can with GLP-1R specifically bind antibody and its with the fused protein of GLP-1
EP3209332B1 (en) * 2014-10-23 2021-05-26 Amgen Inc. Reducing viscosity of pharmaceutical formulations
EP3247400A1 (en) * 2015-01-18 2017-11-29 Biogen MA Inc. Formulations and screening of biological therapeutic agents
US10485870B2 (en) 2015-02-11 2019-11-26 Gmax Biopharm Llc. Stable pharmaceutical solution formulation of GLP-1R antibody fusion protein
WO2017180594A1 (en) * 2016-04-13 2017-10-19 Medimmune, Llc Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
US20210087236A1 (en) * 2016-08-15 2021-03-25 The University Of North Carolina At Chapel Hill Tardigrade disordered proteins as protein stabilizers
EP3522918A1 (en) 2016-10-06 2019-08-14 Amgen Inc. Reduced viscosity protein pharmaceutical formulations
US10953074B2 (en) * 2017-01-08 2021-03-23 Richard D. Lippman Composition and method for improving sensorineural hearing
JP7377596B2 (en) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド Low viscosity, high concentration evolocumab formulations and their manufacturing method
TW202233228A (en) * 2020-10-19 2022-09-01 美商舒爾人類基因療法公司 Compositions suitable for use in neonates
EP4438035A1 (en) * 2021-11-26 2024-10-02 Genexine, Inc. High concentration administration formulation of hgh fusion protein

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of mature human IGF and EGF via prokaryotic recombinant DNA technology
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5374620A (en) 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
SE9201073D0 (en) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab PROTEIN FORMULATION
CA2489978A1 (en) * 1992-07-31 1994-02-17 Genentech, Inc. Human growth hormone aqueous formulation
US6207640B1 (en) * 1994-04-07 2001-03-27 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
EP0805689A1 (en) * 1995-01-13 1997-11-12 Novo Nordisk A/S A stabilized pharmaceutical formulation comprising a growth hormone and x-lys
US6767892B1 (en) * 1997-11-07 2004-07-27 Chrion Corporation Compositions providing for increased IGF-I solubility
WO1999024062A1 (en) 1997-11-07 1999-05-20 Chiron Corporation Novel igf-i composition and its use
CA2378949C (en) * 1999-07-12 2015-03-31 Grandis Biotech Gmbh Growth hormone formulations
BRPI0017437B8 (en) * 1999-10-04 2021-05-25 Chiron Corp stabilized pharmaceutical composition containing IL-2 polypeptide, method of increasing stability of interleukin-2 in a pharmaceutical composition, and a dry form of the composition
ATE402716T1 (en) * 2002-02-27 2008-08-15 Immunex Corp STABILIZED TNFR-FC FORMULATION WITH ARGININE
CN1668332A (en) * 2002-07-09 2005-09-14 桑多斯股份公司 Liquid formulations with a high concentration of human growth hormone (HGH) comprising glycine
US8158582B2 (en) * 2005-06-02 2012-04-17 Tercica, Inc. Methods for treatment of insulin-like growth factor-1 deficiency
PL3225233T3 (en) * 2005-11-01 2019-12-31 Wyeth Llc Sodium chloride solution for drug reconstitution
EP2049148B1 (en) * 2006-07-06 2016-09-28 Daewoong Co., Ltd. A stable liquid formulation of human growth hormone
EP2281827B1 (en) * 2008-05-08 2013-08-21 Ajinomoto Co., Inc. Protein refolding method

Also Published As

Publication number Publication date
KR101614983B1 (en) 2016-04-22
JP6084036B2 (en) 2017-02-22
US20170143834A1 (en) 2017-05-25
BR112012011539A8 (en) 2017-12-26
CN102665691B (en) 2015-05-27
US20120270782A1 (en) 2012-10-25
HK1175711A1 (en) 2013-07-12
JP6143827B2 (en) 2017-06-07
CA2780554A1 (en) 2011-05-26
KR20120104251A (en) 2012-09-20
EP2501367B1 (en) 2015-01-21
BR112012011539A2 (en) 2016-06-28
RU2012124985A (en) 2013-12-27
AU2010321225B2 (en) 2015-12-03
UA108994C2 (en) 2015-07-10
JP2013510893A (en) 2013-03-28
WO2011060922A1 (en) 2011-05-26
ES2532007T3 (en) 2015-03-23
EP2501367A1 (en) 2012-09-26
MX2012005195A (en) 2012-06-12
CA2780554C (en) 2017-08-15
JP2016020395A (en) 2016-02-04
RU2558821C2 (en) 2015-08-10
AU2010321225A1 (en) 2012-06-07
CN102665691A (en) 2012-09-12

Similar Documents

Publication Publication Date Title
IN2012DN02861A (en)
MX2019012939A (en) Linaclotide-containing formulations for oral administration.
MX2013001677A (en) Stable formulations of linaclotide.
WO2010079468A3 (en) Delivery particle
WO2010084480A3 (en) Delivery particles
WO2010079467A3 (en) Delivery particles
WO2010079466A3 (en) Delivery particles
EP2415749A4 (en) New salvianolic acid compound l, preparation method and use thereof
MX2011012122A (en) Thiophene derivatives.
MX2012001939A (en) Pharmaceutical composition and administrations thereof.
HUE047803T2 (en) Compositions, methods & systems for respiratory delivery of two or more active agents
UA101484C2 (en) Lh liquid formulations
WO2011086093A3 (en) Pharmaceutical compositions for oral administration of insulin peptides
MX2011011511A (en) Salt of abt-263 and solid-state forms thereof.
WO2010092090A3 (en) Novel salts of sitagliptin
WO2011062437A3 (en) Gonadotropin releasing hormone receptor antagonists, manufacturing method thereof, and pharmaceutical composition containing same
JO2973B1 (en) Fumarate Salt Of (alphaS, betaR)-6-Bromo-alfa-[2-(dimethylamino)ethyl]-2- Methoxy-alpha-1-naphthalenyl-beta-phenyl-3- Quinolineethanol
WO2008112368A3 (en) Phenylalkylcarboxylic acid delivery agents
WO2010055082A3 (en) New crystal form of sunitinib malate
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
MX2012007999A (en) Stable growth hormone compounds.
WO2012128582A3 (en) A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
WO2012075015A3 (en) Oral metronidazole pharmaceutical compositions
MX2009007265A (en) Salts, aqueous liquid compositions containing salts of s-(+)-abscisic acid and methods of their preparation.
MX2011007736A (en) Stable growth hormone compounds.